Bioasis Technologies Inc.

Equities

BTI

CA09064N1033

Biotechnology & Medical Research

Delayed Toronto S.E. Other stock markets 16:00:00 21/03/2024 GMT			5-day change	1st Jan Change
0.005 ^CAD	-.--%		-.--%	-.--%

2023	Bioasis Technologies Inc. Announces Terminating the Non-Exclusive Research Collaboration and Licensing Agreement with Chiesi Farmaceutici S.P.A	CI
2023	Bioasis Technologies Slumps 25% As Provides Update on Financial Position	MT

Bioasis Technologies Inc. Appoints Mario Saltarelli as Non-Executive Director of the Bioasis Board of Directors

May 30, 2019 at 09:05 pm

Bioasis Technologies Inc. announced the appointment of Mario Saltarelli, M.D., Ph.D., as non-executive director of the Bioasis board of directors. Dr. Saltarelli served on Bioasis’ scientific advisory board (SAB) since June 2018. Dr. Saltarelli has over 20 years of leadership experience in the biopharmaceutical industry. Currently, he is Chief Medical Officer (CMO) at Entrada Therapeutics, and held CMO positions at Syntimmune and Annexon Biosciences.

Latest news about Bioasis Technologies Inc.

Bioasis Technologies Inc. Announces Terminating the Non-Exclusive Research Collaboration and Licensing Agreement with Chiesi Farmaceutici S.P.A	20/06/23	CI
Bioasis Technologies Slumps 25% As Provides Update on Financial Position	06/02/23	MT
Bioasis Technologies Provides Update on Financial Position; Down 11% on Friday	06/02/23	MT
Bioasis Technologies Explores and Evaluates Strategic Alternatives	24/01/23	CI
Midatech Pharma plc cancelled the acquisition of Bioasis Technologies Inc..	22/01/23	CI
Bioasis Technologies Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended November 30, 2022	19/01/23	CI
Midatech Pharma plc entered into a definitive agreement to acquire Bioasis Technologies Inc. from The Lind Partners, LLC and others for $5.5 million.	12/12/22	CI
Bioasis Technologies Inc. Reports Earnings Results for the Second Quarter and Six Months Ended August 31, 2022	28/10/22	CI
Bioasis Technologies Inc. Reports Earnings Results for the First Quarter Ended May 31, 2022	29/07/22	CI
Bioasis Technologies Buys Phase 2 Ready Rare Orphan EGF Assets From Norwegian Company	16/06/22	MT
Bioasis Technologies Inc. Reports Earnings Results for the Full Year Ended February 28, 2022	15/06/22	CI
Bioasis Technologies Inc. Auditor Raises 'Going Concern' Doubt	13/06/22	CI
Bioasis Technologies and Neuramedy of South Korea Enter into Research Collaboration and License Agreement	11/05/22	MT
Bioasis Technologies Inc. and Neuramedy Co Ltd Enter into Research Collaboration and License Agreement	10/05/22	CI
Bioasis Technologies to Collaborate on Research with Johnson & Johnson's Janssen Biotech Subsidiary	11/04/22	MT
Bioasis Technologies Inc. Enters Research Collaboration with Janssen Biotech, Inc	11/04/22	CI
Bioasis Technologies Raises C$0.2 Million in a Private Placement of Shares	17/02/22	MT
Bioasis Technologies Inc. announced that it has received CAD 0.2002 million in funding	16/02/22	CI
Bioasis Technologies Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended November 30, 2021	20/01/22	CI
Bioasis Technologies Inc. Reports Earnings Results for the Second Quarter and Six Months Ended August 31, 2021	28/10/21	CI
Bioasis Technologies Inc.(TSXV:BTI) dropped from S&P/TSX Venture Composite Index	18/10/21	CI
Bioasis Technologies Brief: nnounces Allowance of Japanese Patent Application in Japan Relating to Fusion Protein Comprising Iduronate-2-sulfatase	09/08/21	MT
Bioasis Technologies Inc. Reports Earnings Results for the First Quarter Ended May 31, 2021	29/07/21	CI
Bioasis Technologies Inc. Appoints Jeffrey Sprouse as Preclinical Program Manager	20/07/21	CI
Bioasis Technologies : Says Study Shows Efficacy of its Peptide for Delivering Drugs to the Central Nervous System	07/07/21	MT

Chart Bioasis Technologies Inc.

Duration

Period

More charts

Company Profile

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

Sector

Biotechnology & Medical Research

More about the company

	1st Jan change	Capi.
BIOASIS TECHNOLOGIES INC.	-.--%	291K
MODERNA, INC.	+46.19%	56.65B
IQVIA HOLDINGS INC.	-6.14%	39.44B
LONZA GROUP AG	+39.19%	39.03B
CELLTRION, INC.	-6.65%	26.86B
ICON PUBLIC LIMITED COMPANY	+12.33%	26.75B
ALNYLAM PHARMACEUTICALS, INC.	-21.78%	19.03B
BIO-TECHNE CORPORATION	-0.35%	12.28B
UNITED THERAPEUTICS CORPORATION	+24.18%	12.26B
MEDPACE HOLDINGS, INC.	+28.38%	12.04B

Other Biotechnology & Medical Research